Comera Life Sciences reports Q3 EPS (10c) vs (20c) last year

Reports Q3 revenue $136,310 vs $234,922 last year. “Comera continues to generate significant momentum, by expanding our patent portfolio, strengthening our cash position and advancing key partnerships. These accomplishments allow us to continue executing on our core value drivers, and increase value for our shareholders and partners,” said Jeffrey Hackman, Chairman and Chief Executive Officer of Comera. “As our business advances and we execute our goals and drive our value proposition, we remain focused on our mission to improve patient quality of life and reduce healthcare costs by leveraging our SQore(TM) platform to transform the delivery of biologics from intravenous to self-administered subcutaneous forms.”